Helen Nadel

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Paul A. Meyers, Cindy L. Schwartz, Mark Krailo et al. · Journal of Clinical Oncology · 2008 · 748 citations · Full text

Medicine, Oncology, Pharmacology +14

Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

Paul A. Meyers, Cindy L. Schwartz, Mark Krailo et al. · Journal of Clinical Oncology · 2005 · 719 citations · Full text

Medicine, Oncology, Pharmacology +15

Long-term Risk of CKD in Children Surviving Episodes of Acute Kidney Injury in the Intensive Care Unit: A Prospective Cohort Study

Cherry Mammen, Abdullah Al Abbas, Peter Skippen et al. · American Journal of Kidney Diseases · 2011 · 572 citations

Medicine, Nephrology, Pediatrics +13

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 421 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Jeremy Whelan, Stefan Bielack, Neyssa Marina et al. · Annals of Oncology · 2014 · 333 citations · Full text

Medicine, Oncology, Surgery +15